test project

What is the disease definition and natural history of acute lymphoblastic leukemia?

The supplied documents define acute lymphoblastic leukemia (ALL) as "A group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation" and note synonymous terminology including "ALL, Acute lymphoblastic leukemia/lymphoma, Acute lymphocytic leukemia, Precursor lymphoid neoplasm." The documents do not provide WHO or ICC disease classification schemas, and they do not explicitly define B-cell versus T-cell lineage classifications. Clinical presentation and natural history information relevant to cohort construction includes that patients "may present with symptoms, frequently including lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage or they may remain asymptomatic," and that disease can involve marrow, blood, and extranodal tissues because "the abnormal cells can infiltrate any organ or tissue." The documents also describe relapse patterns and age-related treatment differences: adult ALL induction regimens achieve "complete response rates that range from 60% to 90%" but "Responses were short lived, with most of these patients experiencing disease relapse," while adolescents and young adults are described as "a unique population" in whom "Treatment regimens can vary significantly depending on whether they receive care in a pediatric or in an adult setting" and who have "distinctive care needs, social risk factors, and disease behavior compared with other age groups." The supplied document addresses lineage classifications and some relapse/natural history patterns for acute lymphoblastic leukemia (ALL), particularly in adolescents and young adults (AYAs) with relapsed/refractory disease. It specifically distinguishes “B-cell acute lymphoblastic leukemia (B-ALL)” and “T-cell ALL,” and describes relapsed/refractory ALL as involving “greater treatment resistance” and “higher rates of toxicity.” The document also references relapse states including “CNS relapse” and patients who “achieve a second (or greater) remission (CR2).” However, the document does not provide WHO/ICC disease definitions, comprehensive disease presentation patterns, or detailed pediatric-versus-adult epidemiology and natural history needed for claims-based line-of-therapy cohort construction. The supplied document identifies acute lymphocytic leukemia (ALL) epidemiology and age-related disease patterns in the United States through 2026, but it does not provide WHO/ICC disease definitions, lineage classifications such as B-cell versus T-cell ALL, or detailed relapse/progression natural history relevant to claims-based line-of-therapy construction. The document states that "Acute lymphocytic leukemia is most common in children, adolescents, and young adults, or those 15 to 39 years of age" and that "Acute lymphocytic leukemia is most frequently diagnosed among people aged <20," which supports pediatric and young adult predominance. It also reports U.S. burden estimates including "Estimated New Cases in 2026: 6,250" and "Estimated Deaths in 2026: 1,600." The supplied document only addresses a limited aspect of pediatric acute lymphoblastic leukemia management and does not provide WHO/ICC disease definitions, lineage classifications, relapse patterns, progression course, or pediatric-versus-adult epidemiology relevant to claims-based line-of-therapy cohort construction. The document states that "Pediatric maintenance therapy for acute lymphoblastic leukemia requires prolonged daily administration of 6-mercaptopurine (6-MP), a drug characterized by a narrow therapeutic index and substantial interindividual variability." It also describes that this therapy involves "prolonged daily administration" during pediatric maintenance treatment.

OrphanetNational Cancer InstituteAmerican Society of HematologyNational Cancer Institute, Surveillance, Epidemiology, and End Results ProgramAAPS PharmSciTech

What is the incidence, prevalence, survival and mortality of ALL in the United States, stratified by age group and subtype (B-ALL, T-ALL, Ph-positive)?

The supplied documents provide limited U.S. epidemiology and survival information for acute lymphoblastic leukemia (ALL), primarily for pediatric ALL incidence and adult leukemia survival trends, but they do not provide comprehensive U.S. estimates through 2026, prevalence estimates, mortality rates, or subtype-specific epidemiology for B-ALL, T-ALL, and Philadelphia chromosome-positive ALL. One CDC report states that “Acute lymphoblastic leukemia (ALL) is the most prevalent cancer among children and adolescents in the United States” and reported that “Overall incidence of pediatric ALL during 2001–2014 was 34.0 cases per 1 million persons and among all racial/ethnic groups was highest among Hispanics (42.9 per 1 million).” The same report noted that “Both overall and among Hispanics, pediatric ALL incidence increased during 2001–2008 and remained stable during 2008–2014.” A separate population-based survival study stated that “The lifetime risk of developing leukemia in the United States is 1.5%” and that “Five-year net survival was estimated using data for 370,994 patients from 43 registries in 37 states and in 6 metropolitan areas, covering approximately 81% of the adult (15–99 years) US population,” but the excerpt provided does not include ALL-specific survival values. In the United States, SEER reports that “The rate of new cases of acute lymphocytic leukemia was 1.9 per 100,000 men and women per year” and “The death rate was 0.4 per 100,000 men and women per year,” with “Estimated New Cases in 2026: 6,250” and “Estimated Deaths in 2026: 1,600.” SEER also states that “In 2023, there were an estimated 126,118 people living with acute lymphocytic leukemia in the United States” and that “5-YearRelative Survival: 73.2% (2016–2022).” Age-related epidemiology is described as follows: “Acute lymphocytic leukemia is most common in children, adolescents, and young adults, or those 15 to 39 years of age,” “Acute lymphocytic leukemia is most frequently diagnosed among people aged <20,” and Orphanet reports that “The peak incidence occurs between 2 and 5 years of age.” The supplied documents do not provide U.S. incidence, prevalence, survival, mortality, or subtype distribution estimates specifically for B-ALL, T-ALL, or Philadelphia chromosome-positive ALL. The supplied document provides childhood lymphoid leukaemia 5-year net survival estimates for multiple countries in 2021, but it does not provide United States-specific incidence, prevalence, mortality, subtype distribution, or subtype-specific epidemiology for acute lymphoblastic leukemia (ALL), including B-ALL, T-ALL, or Philadelphia chromosome-positive ALL. The document reports that childhood cancer survival for lymphoid leukaemia reached high levels in several countries, including “GBR 2021 AGEGROUP_YEARSLESS20 = 92.5 [90.2-94.3]”, “DEU 2021 AGEGROUP_YEARSLESS20 = 90.6 [87.1-93.2]”, and “DNK 2021 AGEGROUP_YEARSLESS20 = 92.2 [88.3-94.8]”. No data through 2026 for the United States are included. The supplied document does not provide numerical estimates for incidence, prevalence, survival, or mortality of acute lymphoblastic leukemia (ALL) in the United States through 2026, nor does it provide subtype-specific epidemiology for B-ALL, T-ALL, or Philadelphia chromosome-positive ALL. The document does identify adolescents and young adults (AYAs) as a distinct population with differing disease behavior and treatment settings, and it references major ALL subtypes including B-cell and T-cell ALL. It also states that pediatric-inspired frontline regimens are recommended for AYAs with B-ALL or T-ALL.

CDC / NCHSNational Cancer Institute, Surveillance, Epidemiology, and End Results ProgramOrphanetWorld Health OrganizationAmerican Society of Hematology

What are the clinically important immunophenotypic and molecular subtypes of ALL?

The supplied documents identify acute lymphoblastic leukemia (ALL) broadly as “a group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation,” but they do not provide a comprehensive listing of immunophenotypic, cytogenetic, molecular, Philadelphia chromosome, prognostic, or biomarker-defined ALL subtypes for claims-based cohort definition. The relapsed/refractory ASH guideline specifically references “ALL subsets (T-cell ALL)” and discusses “immunotherapy” and “targeted therapies,” while the frontline guideline states that “higher-risk subsets” and “targeted agents” are clinically relevant in management decisions. No explicit cytogenetic abnormalities, molecular alterations, Philadelphia chromosome-positive/negative categories, or named targetable biomarkers are enumerated in the provided documents. The supplied document identifies Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph-positive ALL) as a clinically important molecular/cytogenetic subtype in adult ALL treatment. It states that “inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage,” and that “Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.” The document also notes prognostic implications for this subtype, stating that “remissions are generally short with conventional ALL chemotherapy clinical trials.” The document does not provide additional immunophenotypic subtypes, broader cytogenetic or molecular alteration categories, prognostic subtype groups, or other targetable biomarkers. The supplied document identifies clinically relevant immunophenotypic subtypes of acute lymphoblastic leukemia (ALL), specifically B-cell ALL and T-cell ALL, and describes marker-defined lineage assignment by flow cytometry. B-ALL was characterized by expression of "pan B-cell markers (CD19,CD22 and cytoplasmic CD79a)" with many cases expressing CD10, while T-ALL was characterized by "cytoplasmic CD3 and CD5." The document also notes aberrant myeloid marker expression in some B-ALL cases and describes immunophenotyping as important for "diagnosis, accurate classification, subtyping and treatment programs." However, the document does not provide a comprehensive description of clinically important cytogenetic abnormalities, molecular alterations, Philadelphia chromosome status, prognostic subtype groups, or targetable biomarkers for U.S. ALL patients through 2026. The documents identify clinically important immunophenotypic ALL subtypes including B-cell and T-cell categories. One source states that the WHO system recognizes “Precursor B cell ALL,” “Precursor T cell ALL,” and “Mature B cell ALL (Burkitt type ALL),” while another notes that “the only subtype recognized by the World Health Organization’s International Consensus Classification is early T-cell precursor ALL.” The materials also identify Philadelphia chromosome-related disease biology, including “Philadelphia chromosome-like ALL (Ph-like ALL)” as “a precursor B-cell ALL that results in a change of the chromosomes on the leukemia cells.” Cytogenetic and molecular characterization is described broadly through “genomic subtypes,” “whole transcriptome, exome, or genome sequencing,” “immunophenotyping and cytogenetic testing,” and “specific genomic alterations,” but the supplied documents do not provide a complete enumeration of clinically important cytogenetic abnormalities, molecular alterations, prognostic subtype groups, or targetable biomarkers through 2026.

OrphanetAmerican Society of HematologyNational Cancer InstituteWHOOpen web

How is ALL diagnosed and what confirmatory workup is required?

The supplied document identifies acute lymphoblastic leukemia (ALL) as "a group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation" and states that it "primarily affects the bone marrow and peripheral blood." It also notes that "the abnormal cells can infiltrate any organ or tissue" and describes common presenting features including "lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage." However, the documents do not provide diagnostic criteria or confirmatory workup details such as bone marrow evaluation methods, flow cytometry, cytogenetic testing, molecular diagnostics, imaging/CNS assessment, or laboratory testing used for subtype classification, treatment initiation, or claims cohort identification. The supplied document is a frontline management guideline for adolescents and young adults with acute lymphoblastic leukemia and does not describe detailed diagnostic criteria or confirmatory diagnostic workup for establishing ALL diagnosis or subtype classification. The document identifies disease categories relevant to treatment initiation, including “B-cell or T-cell acute lymphoblastic leukemia (B-ALL/T-ALL) or T-cell acute lymphoblastic lymphoma (T-LBL/LLy),” and discusses frontline therapy recommendations and therapeutic drug monitoring for asparaginase management. The document does not provide specific recommendations or criteria regarding bone marrow evaluation, flow cytometry, cytogenetic testing, molecular diagnostics, imaging, CNS assessment, or laboratory diagnostic workup. The supplied document concerns management recommendations for relapsed/refractory acute lymphoblastic leukemia (ALL) in adolescents and young adults and does not describe the diagnostic criteria or confirmatory workup used to establish ALL diagnosis and subtype classification. The document references disease subsets and central nervous system (CNS)-directed therapy but does not provide details on bone marrow evaluation, flow cytometry, cytogenetic testing, molecular diagnostics, imaging/CNS assessment methods, or laboratory workup for treatment initiation or claims cohort identification. The supplied document discusses remission induction therapy for adult acute lymphoblastic leukemia (ALL) and mentions treatment considerations for newly diagnosed and Philadelphia chromosome–positive ALL, but it does not describe the diagnostic criteria or confirmatory diagnostic workup used to establish ALL diagnosis or subtype classification. The document does not provide information on bone marrow evaluation, flow cytometry, cytogenetic testing, molecular diagnostics, imaging or CNS assessment, or laboratory workup for treatment initiation or claims cohort identification. The supplied documents indicate that NCCN Guidelines through 2026 address acute lymphoblastic leukemia (ALL) diagnosis and classification with emphasis on subtype classification using immunophenotype and cytogenetic/molecular markers, as well as risk assessment and treatment strategies. However, the documents provided do not contain the detailed diagnostic criteria or confirmatory workup elements requested, such as specific bone marrow evaluation parameters, flow cytometry panels, cytogenetic assays, molecular diagnostics, CNS/imaging assessment, or laboratory workup protocols for treatment initiation or claims cohort identification.

OrphanetAmerican Society of HematologyNational Cancer InstituteOpen web

How is ALL risk-stratified at diagnosis, and which patient characteristics drive cohort segmentation and treatment eligibility (age, comorbidity, performance status, organ function)?

The supplied document discusses treatment approaches for newly diagnosed adult acute lymphoblastic leukemia (ALL), including distinctions for Philadelphia chromosome (Ph)-positive disease, but it does not describe formal risk stratification systems, claims-based cohort segmentation methods, age-based eligibility thresholds, performance status criteria, comorbidity burden measures, organ function criteria, or minimal residual disease (MRD) status definitions. The document states that “Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline” and that “Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.” It also notes that “If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials.” The supplied documents describe adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) as a distinct population and note that frontline treatment decisions differ between pediatric and adult treatment settings. They also state that allogeneic hematopoietic stem cell transplantation in first remission “may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy,” implying some form of risk stratification and response assessment. However, the documents do not specify the diagnostic risk stratification systems, claims-based cohort segmentation methods, age cutoffs for treatment eligibility, performance status criteria, comorbidity burden measures, organ function requirements, or minimal residual disease (MRD) definitions used in United States patients through 2026. The supplied documents indicate that NCCN guidelines for acute lymphoblastic leukemia (ALL) through 2026 emphasize “classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers” and “risk assessment and stratification for risk-adapted therapy.” The documents also specify that treatment strategies are differentiated for “Philadelphia chromosome (Ph)-positive and Ph ...” disease categories. However, the provided materials do not describe the detailed risk stratification systems, age-based eligibility thresholds, performance status criteria, comorbidity burden measures, organ function requirements, minimal residual disease criteria, or the demographic and clinical cohort segmentation variables used in claims-based line-of-therapy analyses.

National Cancer InstituteAmerican Society of HematologyOrphanetOpen web

What are the current guideline-recommended first-line regimens for ALL, by treatment setting (induction, consolidation, maintenance, MRD-positive) and guideline preference category (e.g., NCCN Preferred / Other Recommended / Useful in Certain Circumstances)?

The supplied documents do not provide a comprehensive list of United States first-line treatment regimens for acute lymphoblastic leukemia across induction, consolidation, maintenance, and MRD-positive settings stratified by guideline preference categories. The documents do identify some guideline or cooperative-group treatment approaches and disease subsets. An ASCO Educational Book review states that “Contemporary COG HR ALL treatment regimens were developed from the BFM-76 regimen, with subsequent changes that led to development and refinement of a so-called augmented BFM (ABFM) regimen used today,” and notes that “introduction of the tyrosine kinase inhibitor imatinib has led to dramatic outcome improvements for children and adolescents with Philadelphia chromosome–positive ALL.” A pediatric maintenance-focused recommendation document from the French Society for Childhood and Adolescent Cancer and Leukemia states that “Maintenance therapy is the last phase of treatment for acute lymphoblastic leukemia in children and adolescents” and that it “is an essential phase of treatment that reduces the risk of relapse.” An ASH 2026 guideline document addresses relapsed/refractory AYA ALL rather than first-line disease, reporting that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The supplied documents identify two major guideline bodies relevant to frontline acute lymphoblastic leukemia (ALL) management in the United States as of 2025–2026: the NCCN and the American Society of Hematology (ASH). The NCCN Pediatric ALL Version 2.2025 guideline states that it addresses “risk assessment and stratification of risk-adapted therapy” and includes “treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL,” but the supplied text does not provide specific first-line induction, consolidation, maintenance, or MRD-positive regimens, nor preference categories. The ASH 2026 AYA ALL guideline states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy,” and that “The use of targeted agents in frontline therapy is increasingly supported,” but the supplied excerpts do not enumerate regimen names, treatment phases, MRD-directed regimens, or formal preference categories. The supplied documents do not provide a comprehensive list of U.S. major clinical guideline recommendations, versions, preference categories, or complete first-line regimens across induction, consolidation, maintenance, and MRD-positive settings for acute lymphoblastic leukemia. The documents only describe selected induction-treatment concepts and asparaginase-related recommendations for specific populations. For adult ALL induction, the NCI PDQ document states that "Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline," and that some regimens "also add other drugs, such as asparaginase or cyclophosphamide." For Ph-positive ALL, the same document states that "Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL." Separate consensus-panel documents for adolescent and young adult patients state that "Asparaginase is an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma" and describe use of "pediatric/pediatric-inspired regimens incorporating asparaginase for treating adolescent and young adult (AYA) and adult populations." The supplied documents do not provide a complete accounting of U.S. first-line treatment regimens for acute lymphoblastic leukemia across induction, consolidation, maintenance, and MRD-positive settings by guideline preference category. The documents only identify limited guideline-related statements. One document states that "guidelines from the National Comprehensive Cancer Network now recommend consideration of pediatric inspired treatment" for adolescent and young adult patients with ALL. Another document describes the "American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults," which "cover[] remission reinduction and consolidation" and include recommendations such as "the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction." The documents do not provide the requested full stratification by induction, consolidation, maintenance, MRD-positive settings, preference categories, or comprehensive disease subtype segmentation for all patients. The supplied documents do not provide a comprehensive set of major U.S. clinical guideline recommendations for first-line acute lymphoblastic leukemia treatment across induction, consolidation, maintenance, and MRD-positive settings stratified by guideline preference categories. One FDA document describes a regimen used with ponatinib for newly diagnosed Philadelphia chromosome-positive ALL in adults: “Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.” The pediatric evidence-based review documents state that “allogeneic SCT may be considered for hypodiploid ALL and persistent minimal residual disease corrected (MRD) positivity in ALL in CR1 or greater,” and also note that “preliminary tyrosine kinase inhibitor (TKI) data demonstrate that early outcomes are comparable for allogeneic SCT and chemotherapy + imatinib” for children with Ph+ ALL in CR1. The supplied documents identify NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia and pediatric acute lymphoblastic leukemia, including risk-stratified and frontline management concepts, but they do not provide the specific first-line treatment regimens, induction/consolidation/maintenance protocols, MRD-positive regimens, or preference categories requested. The adult ALL NCCN guideline documents state that they provide "risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults), assessment of minimal residual disease," while the pediatric guideline states that it "focuses on the frontline and relapsed/refractory management of pediatric ALL." The pediatric guideline also identifies high-risk groups including "T-ALL" and "infant ALL." No guideline version dated 2026-09-22, no regimen names, and no recommendation categories are present in the supplied text. The supplied documents identify NCCN Clinical Practice Guidelines as major U.S. clinical guidelines for acute lymphoblastic leukemia (ALL), including adult ALL Version 2.2024 and Pediatric ALL Version 2.2025. The documents state that these guidelines cover “risk assessment and stratification for risk-adapted therapy” and “treatment strategies” for multiple disease subtypes and patient groups, including “Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients” and pediatric “BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.” However, the documents provided do not include the actual first-line treatment regimens, induction/consolidation/maintenance recommendations, MRD-positive recommendations, or preference categories requested in the question. The supplied documents identify the National Comprehensive Cancer Network (NCCN) pediatric and adult acute lymphoblastic leukemia (ALL) guidelines and state that they provide treatment recommendations for frontline and relapsed/refractory management, but they do not provide the specific first-line treatment regimens across induction, consolidation, maintenance, or MRD-positive settings requested in the question. The documents also do not provide guideline preference categories, detailed subtype-specific regimen recommendations, or risk/biomarker-stratified first-line regimen tables. One document specifies "Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology," while another specifies "NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017." The supplied documents identify guideline bodies and some treatment-structure and stratification concepts for acute lymphoblastic leukemia (ALL), but they do not provide a complete list of first-line treatment regimens across induction, consolidation, maintenance, and MRD-positive settings stratified by guideline preference category. The Medscape summary updated March 17, 2026 states that ALL therapy includes “an induction phase with a goal of achieving complete remission (CR)” followed by “a consolidation phase to maintain CR,” and that follow-up is “with maintenance therapy or allogeneic hematopoietic stem cell transplantation (HSCT).” It also states that treatment decisions may be influenced by “Philadelphia chromosome (Ph)(BCR::ABL1) status,” “Presence of CD20-positive disease,” “Cell origin (B-cell vs T-cell),” and “Minimal residual disease (MRD) status.” The ASH document identifies itself as the “American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults,” but the supplied text does not include the specific frontline regimens, recommendation strengths, or preference categories requested.

American Society of Clinical Oncology Educational BookBulletin du cancerBlood advancesJournal of the National Comprehensive Cancer Network : JNCCNNational Cancer InstituteAmerican journal of hematologyJournal of Clinical OncologyAmerican Society of HematologyFDABiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOpen web

What are the guideline-recommended regimens for later-line, relapsed, or refractory ALL, by treatment setting and guideline preference category?

The supplied documents discuss recommendations for relapsed/refractory acute lymphoblastic leukemia (ALL), including immunotherapy, targeted therapy, transplantation, and CNS-directed therapy, but they do not provide a complete regimen-by-regimen listing organized by treatment setting, line of therapy, and guideline preference category for all patients in the United States as of 2026-09-22. The ASH 2026 guideline for adolescents and young adults (AYAs) states that recommendations "focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy" and that "Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction." The NCCN Guidelines Insights document states that recommendations for relapsed/refractory ALL include "more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation," but the provided text does not enumerate specific preferred regimens, later-line sequences, or preference categories. The supplied documents do not provide a complete listing of U.S. guideline-recommended regimens for relapsed, refractory, and later-line acute lymphoblastic leukemia organized by treatment setting, line of therapy, and guideline preference category. The NCCN documents only state that the guidelines include “treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients,” but the excerpts provided specifically note that the selection “focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.” The ASH 2026 guideline document specifically addresses “management of relapsed/refractory ALL in adolescents and young adults” and states that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” while also addressing “T-cell ALL,” “CNS relapse,” and “the role of consolidation with allogeneic transplant.” The documents do not provide the full regimen tables, later-line sequencing, or NCCN preference categories requested. The supplied documents do not provide major clinical guideline recommendations organized by treatment setting, line of therapy, preference category, disease subtype, or transplant/cellular therapy pathways for relapsed, refractory, and later-line acute lymphoblastic leukemia in the United States as of 2026-09-22. The documents only identify selected therapies and populations in relapsed/refractory ALL, including clofarabine for pediatric patients after at least two prior regimens and references to studies involving blinatumomab and inotuzumab ozogamicin in relapsed/refractory adult ALL. One document states that clofarabine "is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens." Another document references "adult patients with relapsed or refractory acute lymphoblastic leukemia receiving zero or one prior salvage therapy," and another references "Relapsed/Refractory Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia." The supplied documents do not provide major United States clinical guideline recommendations, preference categories, or organized line-of-therapy tables for relapsed, refractory, or later-line acute lymphoblastic leukemia as of 2026-09-22. The documents do describe investigational and salvage approaches in relapsed/refractory ALL settings, including venetoclax-based regimens in relapsed/refractory T-ALL/LBL, CD7 CAR-T therapy in relapsed/refractory T-ALL/LBL, and comparisons between CAR-T therapy and allogeneic HSCT in relapsed/refractory B-ALL. Reported treatment approaches include “Ven monotherapy,” “Ven + hypomethylating agent,” “Ven + chemotherapy,” “Ven + nelarabine,” “Ven + targeted agent,” and “Ven + navitoclax” for heavily pre-treated relapsed/refractory T-ALL/LBL patients, while cellular and transplant therapies discussed include “autologous CD7 CAR T-cell therapy,” “stem cell transplantation (SCT),” “Allogenic Hematopoietic Stem Cell Transplantation (HSCT),” and “CAR-T Cell Therapy.” The supplied document discusses relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescents, and young adults in the context of CAR-T-cell therapy and bridging therapy, but it does not provide a comprehensive list of United States major clinical guideline regimens by treatment setting, line of therapy, or preference category. It states that "there is currently no available guidelines" for the bridging period before CAR-T-cell reinfusion and describes an effort to "define recommendations of treatment in each situation of relapsed or refractory B-ALL, Ph+/ABL-like B-ALL and in case of CNS disease or non-CNS extra medullary disease, precising the specific place of immunotherapy." The document also identifies CAR-T cells as a major therapeutic modality in relapsed/refractory B-ALL and references disease subtype stratification including "Ph+/ABL-like B-ALL" and CNS versus non-CNS extramedullary disease. The supplied documents identify that NCCN guidelines for acute lymphoblastic leukemia (ALL) include recommendations for “risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults),” and that pediatric NCCN guidelines address “frontline and relapsed/refractory management of pediatric ALL,” including “hematopoietic stem cell transplantation.” However, the documents provided do not list specific relapsed, refractory, or later-line regimens, do not provide line-of-therapy tables, do not identify guideline preference categories, and do not specify cellular therapy regimens or transplant sequencing recommendations. One document also identifies the topic of “Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults: Progress and Challenges,” but provides no regimen-level recommendations in the supplied text. The supplied document does not provide major clinical guideline recommendations for relapsed, refractory, or later-line acute lymphoblastic leukemia (ALL), including treatment setting, line of therapy, guideline preference categories, disease subtype stratification, or cellular therapies. It does contain limited statements relevant to transplantation and Philadelphia chromosome (Ph)-positive ALL in the context of remission duration and treatment considerations. Specifically, the document states that “Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials” and that “If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials.” The supplied documents do not contain major clinical guideline recommendations, preference categories, treatment-setting organization, transplant guidance, or cellular therapy recommendations for relapsed, refractory, or later-line acute lymphoblastic leukemia. The documents only provide FDA labeling indications for specific agents in relapsed or refractory ALL/T-ALL settings after at least two prior regimens. Nelarabine is indicated for "T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)" in patients "whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens." Clofarabine is indicated for "pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens." The supplied documents identify that NCCN Clinical Practice Guidelines for acute lymphoblastic leukemia (ALL) include recommendations on “risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults)” and that pediatric ALL guidelines address “treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.” The documents also state that the pediatric guidelines focus on “the diagnosis of and management of pediatric T-ALL.” However, the supplied excerpts do not provide the requested relapsed/refractory or later-line regimens, line-of-therapy recommendations, preference categories, cellular therapies, or transplant recommendations. The supplied documents identify that NCCN maintains "NCCN Guidelines Version 3.2026 - Acute Lymphoblastic Leukemia" and "NCCN Guidelines with Evidence Blocks Version 2.2026," but they do not provide the actual recommended regimens, treatment settings, lines of therapy, preference categories, subtype stratification, or cellular/transplant therapy recommendations requested. One supplementary document mentions blinatumomab in "chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients," but no organized guideline recommendations for relapsed, refractory, or later-line ALL are included in the provided text.

American Society of HematologyJournal of the National Comprehensive Cancer Network : JNCCNBlood advancesDr.Reddy's Laboratories IncJournal of Clinical OncologyJCO Precision OncologyBulletin du cancerJCO Oncology PracticeNational Cancer InstituteAlembic Pharmaceuticals LimitedAmneal Pharmaceuticals LLCUS Food and Drug AdministrationOpen web

Which therapies are FDA-approved (or otherwise officially approved) for ALL, with label indication, approved line, biomarker restriction, and approval date?

The supplied documents identify three FDA-approved drug products for acute lymphoblastic leukemia (ALL): clofarabine, imatinib mesylate, and dasatinib. Clofarabine injection is indicated for “pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,” with “Initial U.S. Approval: 2004.” Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy,” with “Initial U.S. Approval: 2001.” Dasatinib tablets are indicated for “Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy” in adults and for “pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy,” with “Initial U.S. Approval: 2006.” The documents provide biomarker restrictions through the requirement for “Philadelphia chromosome-positive (Ph+)” disease where applicable, but they do not provide billing codes, HCPCS codes, NDC-based coding summaries, biologics approvals, or cellular therapy approvals for ALL. The supplied documents identify several FDA-approved therapies for acute lymphoblastic leukemia (ALL) in the United States, but they do not provide comprehensive coverage of all approved drugs, biologics, cellular therapies, or billing/product coding identifiers. SPRYCEL (dasatinib) is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” establishing a biomarker restriction of Ph+ status and a relapsed/refractory treatment setting; the label also states “Initial U.S. Approval: 2006.” Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy,” again restricting use to Ph+ ALL. ARRANON (nelarabine) appears in the FDA Drugs@FDA record with “ORIG 1 AP 2005-10-28,” but the provided text does not include the ALL indication, treatment line, biomarker restriction, or coding identifiers. The supplied documents identify FDA-approved treatments for acute lymphoblastic leukemia including nelarabine and clofarabine, but they do not provide a complete list of all approved drugs, biologics, or cellular therapies in the United States as of 2026-09-22, and they do not provide billing or product coding identifiers. Nelarabine injection received "Initial U.S. Approval: 2005" and is indicated for "T-cell acute lymphoblastic leukemia (T-ALL)" in "adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens," establishing a relapsed/refractory setting after at least two prior regimens and a biomarker/disease restriction to T-cell ALL. Clofarabine injection received "Initial U.S. Approval: 2004" and is indicated for "pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens," defining a pediatric relapsed/refractory treatment line after at least two prior regimens without an additional biomarker restriction stated in the supplied text. The supplied document discusses hematopoietic stem cell transplantation recommendations in pediatric acute lymphoblastic leukemia (ALL), including certain disease settings and biomarkers such as Philadelphia chromosome positive (Ph+) ALL, but it does not provide FDA or other regulatory approvals, approval dates, labeled indications, treatment lines in regulatory labeling, or billing/product coding identifiers for drugs, biologics, or cellular therapies in the United States. The document states that “Allogeneic SCT is recommended for children who: are in second complete remission (CR2) after experiencing an early marrow relapse for precursor-B ALL; experienced primary induction failure, but subsequently achieved a CR1; have T-lineage ALL in CR2; or have ALL in third or greater remission.” It also notes that “the 2005 pediatric ALL evidence-based review (EBR) recommended allogeneic SCT for children with Philadelphia chromosome positive (Ph+) ALL in CR1,” and references “chemotherapy + imatinib,” but no regulatory approval details are given. The supplied documents do not provide a comprehensive list of FDA- or regulator-approved drugs, biologics, or cellular therapies for acute lymphoblastic leukemia, nor do they provide approval dates or billing/product coding identifiers. The documents do identify certain therapies discussed in guideline contexts for relapsed/refractory ALL, including “tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation” and recommendations involving “blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The ASH guideline document specifically addresses adolescents and young adults with relapsed/refractory ALL and states that recommendations focused on “immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy.” No document supplies labeled FDA indications, treatment lines, biomarker restrictions, approval dates, HCPCS/J-codes, NDCs, or other coding identifiers for all approved ALL products. The supplied documents do not provide a complete list of FDA- or regulator-approved drugs, biologics, or cellular therapies for acute lymphoblastic leukemia in the United States, nor do they provide approval dates or billing/product coding identifiers. The documents mention several therapies in the context of ALL management and future or investigational use. One guideline states: “Patients with refractory/relapsed disease have a poor prognosis which highlights the importance of acquiring in the future new therapies such as: blinatumumab, inotuzumab, and CAR-T cells.” Another document describes CAR-T therapy as investigational and notes that “CAR-T therapy may be offered to people when their cancer comes back.” The documents also mention a biomarker-restricted subgroup: “For patients with Philadelphia chromosome positive (Phi+) ALL, post-transplantation tyrosine kinase inhibitors as a systematic maintenance strategy is recommended.” The supplied documents discuss treatment approaches and guideline recommendations for acute lymphoblastic leukemia (ALL), including T-cell ALL and adolescent/young adult ALL, but they do not provide a list of FDA-approved drugs, biologics, or cellular therapies, approval dates, labeled indications, treatment lines, biomarker restrictions, or billing/product coding identifiers. The documents state that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols” and that “The use of targeted agents in frontline therapy is increasingly supported, although further research is needed to optimize this strategy.” They also describe asparaginase as “an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma.” No document supplies the requested regulatory approval tables or coding data. The supplied documents identify two FDA-labeled drugs for acute lymphoblastic leukemia (ALL): mercaptopurine and methotrexate. Mercaptopurine is labeled for “the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” with no explicit biomarker restriction for indication, although TPMT and NUDT15 testing and dose modifications are discussed for toxicity management. Methotrexate Injection is labeled for “the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen.” The documents also include an FDA Drugs@FDA entry for ICLUSIG (ponatinib), but the supplied text does not state an ALL indication, treatment line, biomarker restriction, or approval details specific to ALL. The documents do not provide billing codes, HCPCS/J-codes, NDCs, or other coding identifiers for ALL products. The supplied documents identify FDA-approved tyrosine kinase inhibitor products for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), specifically imatinib mesylate/Gleevec and Sprycel. Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” The biomarker restriction stated is “Philadelphia chromosome positive (Ph+ ALL).” The documents also provide FDA approval history for Gleevec and Sprycel, including “ORIG 1 AP 2003-04-18” for Gleevec and “ORIG 1 AP 2006-06-28” for Sprycel, but they do not provide ALL-specific approval dates, labeled ALL treatment lines for Sprycel, or any billing/product coding identifiers such as HCPCS or J-codes. The supplied documents identify methotrexate and doxorubicin as FDA-labeled products for acute lymphoblastic leukemia (ALL). Methotrexate tablets are indicated for the “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” which specifies a maintenance treatment setting and includes both adult and pediatric patients without a biomarker restriction. Doxorubicin hydrochloride injection is indicated “for the treatment of acute lymphoblastic leukemia,” and the labeling also provides dosing for “Metastatic Disease, Leukemia, or Lymphoma,” including single-agent and combination therapy dosing, but no biomarker restriction is stated. The documents do not provide approval dates, HCPCS/CPT/NDC billing or product codes, or a complete list of all FDA-approved drugs, biologics, or cellular therapies for ALL in the United States. The supplied documents discuss clinical practice guidelines and diagnostic/cytogenetic stratification for acute lymphoblastic leukemia (ALL), including pediatric, adult, Philadelphia chromosome (Ph)-positive and Ph-negative disease, but they do not provide a list of FDA-approved drugs, biologics, or cellular therapies, nor approval dates, labeled indications, treatment lines, biomarker restrictions tied to approvals, or billing/product coding identifiers. The NCCN guideline documents state that they focus on “treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL” and “management of ALL, with a focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers.” The cytogenetics document notes that “Ph-like ALL ... can benefit from targeted therapy,” but does not identify approved products or regulatory details. The supplied documents identify methotrexate products as FDA-labeled therapies for acute lymphoblastic leukemia (ALL) in the United States. Methotrexate Injection is indicated for “treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen,” while methotrexate tablets are indicated for “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.” The documents do not provide approval dates, biomarker restrictions, cellular therapies, biologics, or billing/product coding identifiers, and they do not comprehensively list all FDA-approved ALL therapies as of 2026-09-22. The supplied documents identify doxorubicin products as approved/indicated for acute lymphoblastic leukemia in the United States. One label states: “Doxorubicin is indicated for the treatment of acute lymphoblastic leukemia,” and another states that “DOXOrubicin HCl Injection, USP and DOXOrubicin HCl for Injection, USP have been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia.” The documents do not provide FDA approval dates, biomarker restrictions, treatment-line limitations, or billing/product coding identifiers for acute lymphoblastic leukemia, nor do they identify other approved ALL drugs, biologics, or cellular therapies. The documents discuss several therapies used or under development for acute lymphoblastic leukemia (ALL), including imatinib for newly diagnosed Philadelphia chromosome–positive ALL, blinatumomab and inotuzumab in relapsed/refractory ALL, and CAR-T cells being tested in ALL. However, the documents do not provide comprehensive FDA or other official regulatory approval information, approved labeling language, approval dates, treatment-line specifications, billing/product codes, or complete biomarker restrictions. The only explicit biomarker-linked treatment statement is for “Ph-positive ALL” or “Philadelphia chromosome positive (Phi+) ALL” in relation to imatinib and tyrosine kinase inhibitors. One document describes a clinical trial regimen for “adult patients with Ph Negative ALL,” but it is explicitly a study and not an approval document. Another document lists FDA Drugs@FDA product information for methotrexate formulations, including NDA and submission dates, but it does not state an ALL indication, treatment line, biomarker restriction, approval for ALL, or billing/product coding identifiers.

Dr.Reddy's Laboratories IncApotex CorpBluePoint LaboratoriesUS Food and Drug AdministrationSANDOZAlembic Pharmaceuticals LimitedAmneal Pharmaceuticals LLCBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationJournal of the National Comprehensive Cancer Network : JNCCNAmerican Society of HematologyBulletin du cancerNational Cancer Institute (NCI)Journal of Clinical OncologyHikma Pharmaceuticals USA Inc.Hospira, Inc.NOVARTISBRISTOL MYERS SQUIBBSun Pharmaceutical Industries, Inc.Bryant Ranch PrepackPfizer Laboratories Div Pfizer IncCurrent research in translational medicineAlembic Pharmaceuticals Inc.Aurobindo Pharma LimitedNational Cancer InstituteAmerican Society of Clinical Oncology Educational BookMemorial Sloan Kettering Cancer CenterHOSPIRA

How does ALL treatment differ between Ph-positive and Ph-negative disease and by other biomarker or risk segments, and at what point in the journey is biomarker testing expected (at diagnosis vs. at progression)?

The documents distinguish treatment pathways primarily by Philadelphia chromosome/BCR-ABL status, MRD status, and selected biomarkers such as CD20 positivity and BCR-ABL-like phenotype. For Ph-positive ALL, the NCI PDQ states that "inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage" and that "Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials," with consideration of "allogeneic bone marrow transplant" because remissions are short with conventional chemotherapy. For BCR-ABL-negative B-lineage ALL, the trial document evaluates adding blinatumomab to chemotherapy specifically in patients who are "minimal residual disease (MRD) negative after induction and intensification chemotherapy," while also comparing outcomes in patients who are MRD positive and later convert to MRD negative after blinatumomab. Biomarker-directed elements in the protocol include evaluation of "BCR/ABL1-like B-lineage ALL" and optional rituximab use for "CD20 positive patients." The documents indicate biomarker or disease-status assessment at diagnosis and after induction/intensification chemotherapy, including "multiparameter flow cytometric (MFC) assessment of residual blasts" for MRD-based treatment selection, but they do not provide comprehensive U.S. guideline-recommended pathways across all ALL risk groups or all expected testing timepoints. The supplied ASH 2026 guidelines describe that frontline and relapsed/refractory ALL treatment pathways differ for certain higher-risk subsets and disease subsets, but they do not provide a complete biomarker-based treatment algorithm by Philadelphia chromosome status, molecular biomarkers, MRD status, or testing timepoints. For frontline AYA ALL, the guidelines state that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” They also state that “The use of targeted agents in frontline therapy is increasingly supported.” For relapsed/refractory AYA ALL, the guidelines report that recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” including “the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” and they additionally mention “ALL subsets (T-cell ALL), CNS relapse, and the role of consolidation with allogeneic transplant.” The documents do not specify Philadelphia chromosome-directed pathways, MRD-directed treatment changes, required biomarker panels, or when biomarker testing is recommended or expected for all patients. The supplied documents indicate that acute lymphoblastic leukemia treatment and outcomes may differ by Philadelphia chromosome status, including references to “Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL)” and to “Clinical outcome of adult acute lymphoblastic leukemia based on Philadelphia chromosome status and socioeconomic status.” One document also references “BCR-ABL mutation status” in “imatinib-resistant patients,” implying molecular biomarker considerations in Ph+ ALL. However, the documents do not provide guideline-recommended treatment pathways, MRD-based stratification, testing timepoints, or detailed risk-segment recommendations. The supplied documents identify that NCCN maintains U.S. Acute Lymphoblastic Leukemia guidelines and biomarker-testing resources through “NCCN Guidelines Version 3.2026 - Acute Lymphoblastic Leukemia” and the “NCCN Biomarkers Compendium®,” but they do not provide the actual treatment pathways, biomarker-specific recommendations, MRD-directed algorithms, Philadelphia chromosome–specific regimens, risk stratification categories, or testing timepoints requested in the question. The documents do state that the NCCN Biomarkers Compendium includes tests used for “Diagnosis,” “Monitoring,” “Prediction,” and “Prognostication,” and that these tests are “recommended within the NCCN Guidelines.” No detailed ALL treatment algorithms or biomarker-triggered treatment selection rules are included in the supplied text.

National Cancer InstituteNational Cancer Institute (NCI)American Society of HematologyBlood advancesJournal of Clinical OncologyOpen web

What recent FDA approvals or label expansions have occurred in ALL?

The supplied documents identify FDA-related submissions and current labeled acute lymphoblastic leukemia (ALL) indications for GLEEVEC and dasatinib, but they do not comprehensively describe all recent FDA approvals or label expansions for ALL therapies through 2026-09-22. For GLEEVEC, the Drugs@FDA record lists multiple approved supplements, including "SUPPL 63 AP 2024-03-01 Manufacturing (CMC) N/A" and earlier efficacy and labeling approvals, but the document does not state the ALL indication changes associated with those actions. For dasatinib, the labeling states that it is indicated for "Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy" in adults and for "pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy," establishing a biomarker requirement of "Philadelphia chromosome-positive (Ph+)." The dasatinib label also states "Initial U.S. Approval: 2006," but no recent FDA effective dates or expansion approval dates are provided in the supplied text. The supplied FDA Drugs@FDA records show recent supplemental FDA actions for several acute lymphoblastic leukemia therapies, but they do not provide the underlying indication text, label-expansion details, biomarker requirements, or patient populations. For SPRYCEL (dasatinib), the record includes recent actions such as “SUPPL 28 AP 2024-07-31 Labeling STANDARD” and earlier efficacy supplements including “SUPPL 21 AP 2018-12-21 Efficacy PRIORITY.” For ARRANON (nelarabine), the record includes “SUPPL 14 AP 2025-03-11 Labeling STANDARD” and “SUPPL 10 AP 2019-07-31 Efficacy STANDARD.” For ICLUSIG (ponatinib), the record includes “SUPPL 38 AP 2025-10-10 Efficacy STANDARD” and “SUPPL 34 AP 2020-12-18 Efficacy PRIORITY.” The documents do not state the specific ALL indications, label-expansion wording, biomarker requirements, or effective-date language for patients. The supplied document identifies FDA-labeled acute lymphoblastic leukemia (ALL) indications for imatinib mesylate, but it does not describe any recent FDA approvals or label expansions through 2026-09-22. The label states that imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” The biomarker requirement specified for these ALL indications is “Philadelphia chromosome positive (Ph+).” The only approval timing provided is “Initial U.S. Approval: 2001,” and no effective dates for newer approvals or label expansions are included in the supplied material. On March 19, 2024, the FDA granted accelerated approval to ponatinib (Iclusig) with chemotherapy for “adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).” The biomarker/eligibility requirement specified in the indication was Philadelphia chromosome-positive disease. In June 2024, the FDA expanded approval of Blincyto (blinatumomab) to include “adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.” The expanded Blincyto indication therefore changed eligibility to include patients regardless of MRD status, while retaining biomarker requirements of CD19-positive and Philadelphia chromosome-negative disease.

NOVARTISBluePoint LaboratoriesBRISTOL MYERS SQUIBBSANDOZTAKEDA PHARMS USAApotex CorpOpen web

Which approvals or indications in ALL have been withdrawn or restricted (e.g., accelerated-approval withdrawals), and on what dates?

The supplied documents do not identify any acute lymphoblastic leukemia therapy approvals or indications that were withdrawn, restricted, or otherwise modified by regulators, and they do not provide effective dates for such actions. The only relevant regulatory qualification in the documents is for clofarabine injection, where the indication states that it is "based upon response rate" and that there are "no trials verifying an improvement in disease-related symptoms or increased survival." The ICLUSIG record lists multiple FDA supplement actions and dates, including efficacy and labeling supplements, but does not describe any withdrawn or restricted ALL indications. The supplied documents do not identify any acute lymphoblastic leukemia (ALL) therapy approvals or indications in the United States that were withdrawn, restricted, or modified through 2026-09-22. The documents discuss oncology accelerated approvals and withdrawals generally, including examples in lung, breast, and bladder cancers, but they do not name any ALL therapies, indications, or effective dates relevant to ALL patients. The provided documents do not identify any withdrawn acute lymphoblastic leukemia (ALL) indications in the United States through 2026-09-22. They do identify regulatory modifications affecting ALL therapies: on March 19, 2024, the FDA granted “accelerated approval” to ponatinib (Iclusig) with chemotherapy for “adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).” The documents also show regulatory changes for TECARTUS (brexucabtagene autoleucel), including a “REMS Major Modification Approval Letter” dated June 12, 2024, and a “REMS Elimination Approval Letter” dated June 26, 2025, for a product indicated for “Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).”

US Food and Drug AdministrationTAKEDA PHARMS USAJournal of Clinical OncologyOpen web

Which products are used off-label or are compendia-supported for ALL, by line of therapy, and what codes represent each?

The supplied documents identify FDA-labeled therapies for acute lymphoblastic leukemia (ALL) and relapsed/refractory T-cell ALL, including therapy class and prior-line context, but they do not provide off-label uses, compendia-supported uses, compendia status, or coding identifiers. Clofarabine is described as “a nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,” establishing a relapsed/refractory setting after at least two prior lines. Nelarabine is described as “a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens,” also specifying treatment after at least two prior regimens. Methotrexate is identified as “a folate analog metabolic inhibitor” indicated for “treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen” and for “prophylaxis and treatment of adult and pediatric patients with meningeal leukemia,” but no line-of-therapy, off-label, compendia, biologic, cellular therapy, or coding information is supplied. The supplied documents identify several therapies used in acute lymphoblastic leukemia (ALL), including immunotherapy, targeted therapies, CAR-T cellular therapy, and methotrexate, but they do not provide compendia status details, coding identifiers, or a comprehensive off-label-use listing by line of therapy. For relapsed/refractory ALL in adolescents and young adults, the ASH 2026 guideline states that recommendations for remission reinduction and consolidation “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” and that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” CD19 CAR therapy is described as an emerging cellular immunotherapy for B-cell ALL with “remarkable clinical outcomes in adults and children with ALL,” and methotrexate is FDA-indicated for “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.” The documents do not provide HCPCS, CPT, ICD-10, NDC, or other coding identifiers, and they do not explicitly identify any therapy as off-label or compendia-supported. The documents identify FDA-labeled therapies and guideline-supported modalities for acute lymphoblastic leukemia (ALL), but they do not provide compendia status details, coding identifiers, or a comprehensive list of off-label therapies. Methotrexate is described as a “folate analog metabolic inhibitor” indicated for “adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen,” and mercaptopurine is described as a “nucleoside metabolic inhibitor” indicated for “patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.” The ASH 2026 relapsed/refractory ALL guideline addresses later-line therapy concepts in adolescents and young adults, stating that recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” and that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The supplied documents do not provide billing or coding identifiers, explicit compendia classifications, or explicit statements that these uses are off-label. The documents describe several therapies and therapy classes used in acute lymphoblastic leukemia (ALL), including first-line chemotherapy, hematopoietic stem-cell transplantation, targeted therapy, CAR-T cellular therapies, and lymphodepletion regimens, but they do not provide compendia support status, coding identifiers, or a comprehensive off-label use listing. For first-line therapy, one source states that "Modern first-line therapy consists of standard- and high-dose chemotherapy (increasingly inspired to pediatric principles), hematopoietic stem-cell transplantation, and new targeted therapy." For relapsed or refractory B-cell ALL, investigational CAR-T approaches described include TSLPR-CART and commercial tisagenlecleucel CAR T-cell therapy, with one study requiring disease that "is relapsed or refractory after initial systemic therapy and at least one salvage treatment." The supplied documents do not identify NCCN or other compendia recommendations, HCPCS/CPT/ICD coding identifiers, or a complete by-line-of-therapy catalog of off-label therapies for all ALL patients in the United States as of 2026-09-22. The documents discuss asparaginase-containing pediatric-inspired regimens and targeted agents for acute lymphoblastic leukemia (ALL), particularly in adolescents and young adults (AYA), but they do not provide a comprehensive list of off-label therapies, compendia-supported uses, coding identifiers, or detailed line-of-therapy classifications. The available text states that "Asparaginase is an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma" and that "trials of pediatric/pediatric-inspired regimens incorporating asparaginase" have been extended to "adolescent and young adult (AYA) and adult populations." The ASH 2026 guideline document further states that "Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols" and that "The use of targeted agents in frontline therapy is increasingly supported." No compendia status labels, HCPCS/CPT/NDC/ICD coding identifiers, or explicit off-label regulatory determinations are provided in the supplied documents. The documents identify some therapies used for acute lymphoblastic leukemia (ALL), including doxorubicin, pediatric-inspired regimens containing asparaginase, targeted agents, and allogeneic hematopoietic stem cell transplantation. Doxorubicin is FDA-indicated for ALL and is described for use in “Metastatic Disease, Leukemia, or Lymphoma,” but no line-of-therapy designation is provided. ASH guidelines describe “frontline therapy” in adolescents and young adults using “Pediatric-inspired regimens containing asparaginase” and note that “The use of targeted agents in frontline therapy is increasingly supported,” while “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The documents do not provide compendia-supported off-label use determinations, coding identifiers, HCPCS/NDC/CPT identifiers, or a complete line-of-therapy mapping for all drugs, biologics, and cellular therapies in ALL. The documents identify dasatinib (SPRYCEL), a kinase inhibitor, as an FDA-labeled therapy for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) "with resistance or intolerance to prior therapy," which corresponds to a later-line setting after prior treatment. The label also provides a disease-specific dosage for "Ph+ ALL" of "140 mg administered orally once daily." The NCI PDQ document describes induction regimens for adult ALL using combination chemotherapy including "prednisone, vincristine, and an anthracycline," with some regimens adding "asparaginase or cyclophosphamide," and states that "Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials." The supplied documents do not provide compendia status classifications, billing or coding identifiers, cellular therapy coding, or a comprehensive list of off-label therapies across all lines of therapy for ALL. The supplied documents identify some therapies and therapy classes being studied or discussed for acute lymphoblastic leukemia (ALL), but they do not provide a comprehensive United States 2026 list of off-label therapies, compendia-supported uses, line-of-therapy recommendations, or coding identifiers. One clinical trial document describes the addition of venetoclax and blinatumomab to chemotherapy for infants with newly diagnosed ALL, stating that “Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors” and “Blinatumomab is a monoclonal antibody.” Another guideline document states that “the rapid development of immunotherapy has improved the efficacy of adult ALL, and commercial antibodies and CAR-T cell products have been available in China.” The documents do not provide compendia status, NCCN support categories, HCPCS/CPT/NDC/J-codes, or explicit off-label line-of-therapy mappings for all patients in the United States. The documents describe investigational and relapsed/refractory acute lymphoblastic leukemia therapies, including small-molecule combinations and cellular therapies, but they do not provide comprehensive United States off-label or compendia-supported use listings, coding identifiers, or formal line-of-therapy compendia status as of 2026-09-22. One study evaluates the drug combination of calaspargase pegol-mknl, decitabine, and venetoclax in pediatric, adolescent, and young adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma. Another study evaluates a CD19-directed CAR T-cell therapy (AUTO1/obe-cel) in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The supplied documents do not include HCPCS, CPT, ICD-10, NDC, or other coding identifiers, and they do not state NCCN Compendia or other compendia support categories. The supplied documents identify several therapies used or studied in acute lymphoblastic leukemia (ALL), including tyrosine kinase inhibitors, monoclonal antibodies, and cellular therapies, but they do not provide compendia status details, coding identifiers, or a comprehensive off-label listing by line of therapy. For relapsed/refractory ALL and minimal residual disease settings, the documents describe blinatumomab, inotuzumab ozogamicin, rituximab, and autologous chimeric antigen receptor (CAR) cells. For newly diagnosed Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-ALL, a clinical trial document describes use of blinatumomab with dasatinib or imatinib plus chemotherapy. The documents also identify ponatinib (ICLUSIG) as an FDA-approved product, but they do not specify ALL line-of-therapy use, compendia support, or billing/coding identifiers. The supplied documents describe investigational and treatment regimens for acute lymphoblastic leukemia (ALL), including therapies used in newly diagnosed and high-risk or relapsed settings, but they do not provide compendia-supported indications, off-label status determinations, or coding identifiers. Document 0 describes selected use of blinatumomab and cellular therapies in pediatric and young adult patients with high-risk ALL in remission states including CR1, CR2, and CR3 or subsequent relapse settings in the context of haploidentical hematopoietic cell transplantation. Document 1 describes a “pediatric-inspired” chemotherapy regimen for adults aged 18-60 with newly diagnosed Philadelphia chromosome-negative ALL and lists the chemotherapy agents used. No document provides United States compendia status, HCPCS/CPT/NDC coding identifiers, or explicit regulatory off-label classifications. The supplied documents identify that the NCCN Clinical Practice Guidelines for Pediatric Acute Lymphoblastic Leukemia address treatment strategies for multiple ALL subtypes and include recommendations for “frontline and relapsed/refractory management,” but they do not enumerate specific off-label drugs, biologics, cellular therapies, compendia-supported indications, line-of-therapy mappings, or coding identifiers. The documents state that the guidelines include “guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics” and cover “treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.” No HCPCS, CPT, ICD-10, NDC, or other coding identifiers are provided in the supplied text. The supplied documents identify doxorubicin hydrochloride as a drug used in acute lymphoblastic leukemia, but they do not provide the requested comprehensive list of off-label therapies, biologics, cellular therapies, compendia-supported uses, lines of therapy, or coding identifiers for acute lymphoblastic leukemia in the United States as of 2026-09-22. One FDA labeling document states that "DOXOrubicin HCl Injection, USP and DOXOrubicin HCl for Injection, USP have been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia." The documents discussing oncology drug compendia and off-label coverage do not provide specific acute lymphoblastic leukemia therapies, compendia status categories, or line-of-therapy details. The supplied documents identify clofarabine as a nucleoside metabolic inhibitor used in acute lymphoblastic leukemia (ALL) for pediatric patients with relapsed or refractory disease after at least two prior regimens, which corresponds to a later-line therapy setting. The documents state: "Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens." The documents do not provide information on off-label ALL therapies, compendia-supported uses, compendia status, cellular therapies, biologics beyond clofarabine, therapy coding identifiers, or line-of-therapy categorizations for all patients in the United States as of 2026-09-22. The supplied documents identify FDA-labeled therapies for acute lymphoblastic leukemia (ALL), but they do not provide compendia-supported off-label uses, line-of-therapy categorizations beyond resistance/intolerance language, coding identifiers, or cellular therapies. Doxorubicin is described as "indicated for the treatment of acute lymphoblastic leukemia" and is an "anthracycline topoisomerase inhibitor." Dasatinib is described as a "kinase inhibitor" indicated for "adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy" and for "pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy." The supplied documents do not provide a comprehensive list of off-label therapies, compendia-supported uses, lines of therapy, coding identifiers, or therapy classes for acute lymphoblastic leukemia in the United States as of 2026-09-22. The documents do mention immunotherapy approaches including monoclonal antibodies, CAR-T cell products, and blinatumomab in adult or newly diagnosed B-lineage acute lymphoblastic leukemia. One clinical trial document specifically evaluates “combination chemotherapy with blinatumomab” in “newly diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia,” which corresponds to a frontline/newly diagnosed treatment setting. The supplied documents identify that NCCN Guidelines for acute lymphoblastic leukemia (ALL) include "treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients" and that pediatric guidelines include "treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL." However, the documents do not provide specific off-label drugs, biologics, cellular therapies, compendia-supported uses, line-of-therapy details, or coding identifiers for ALL therapies in the United States as of 2026-09-22.

Dr.Reddy's Laboratories IncAlembic Pharmaceuticals LimitedHospira, Inc.American Society of Clinical Oncology Educational BookAmerican Society of HematologyAlembic Pharmaceuticals Inc.Blood advancesHikma Pharmaceuticals USA Inc.Journal of Clinical OncologyNational Cancer Institute (NCI)Memorial Sloan Kettering Cancer CenterAmerican journal of hematologyUS Food and Drug AdministrationNOVARTISNational Cancer InstituteZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiM.D. Anderson Cancer CenterAutolus LimitedTAKEDA PHARMS USASt. Jude Children's Research HospitalJournal of the National Comprehensive Cancer Network : JNCCNJournal of Oncology PracticeAmneal Pharmaceuticals LLCPfizer Laboratories Div Pfizer IncBluePoint LaboratoriesDefault Digital Object Group

How have guideline recommendations for ALL changed over the study period, and on what dates?

The supplied document describes contemporary remission induction approaches for adult acute lymphoblastic leukemia (ALL), including that "Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline" and that some regimens "also add other drugs, such as asparaginase or cyclophosphamide." It also notes a treatment change within a CALGB study involving the "omission of L-asparaginase" midway through the study. For newly diagnosed adult patients with Philadelphia chromosome (Ph)-positive ALL, the document states that "inclusion of imatinib into a relatively standard chemotherapy regimen... may provide a significant survival advantage" and that "Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials." The document further states that "If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials" and that "the use of myeloid growth factors during remission-induction therapy appears to decrease the time to hematopoietic reconstitution." The documents do not provide guideline version histories, dates of recommendation changes, or a chronological evolution of U.S. clinical guidelines through 2026-09-22. The supplied documents describe new 2026 American Society of Hematology (ASH) guidelines for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL), including frontline and relapsed/refractory settings, but they do not provide a longitudinal history of guideline changes over time or prior version dates. For frontline management, the 2026 ASH guideline states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” For relapsed/refractory disease, the 2026 ASH guideline reports that recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” and that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The affected settings and patient subgroups described are AYAs with frontline ALL and AYAs with relapsed/refractory ALL, including “ALL subsets (T-cell ALL), CNS relapse, and the role of consolidation with allogeneic transplant.”

National Cancer InstituteAmerican Society of HematologyBlood advances

What are the published benchmarks for time on treatment, time to next treatment, and PFS (progression-free survival) in ALL by line and key regimen?

The supplied documents contain limited published benchmark information for outcomes in acute lymphoblastic leukemia (ALL), mostly related to remission duration, relapse-free survival objectives, and treatment context rather than comprehensive benchmarks for time on treatment (TOT), time to next treatment (TTNT), or progression-free survival (PFS) by line of therapy and regimen. For newly diagnosed adult ALL induction therapy, the NCI PDQ states that "Current multiagent induction regimens result in complete response rates that range from 60% to 90%" and reports that in Ph-positive ALL treated with imatinib-containing therapy, "most of these patients experiencing disease relapse at a median of 58 days after the start of therapy" and "The responses again were short, with a median duration of 2.2 months." A ClinicalTrials.gov phase III study in newly diagnosed BCR-ABL-negative B-lineage ALL lists overall survival (OS) and relapse-free survival (RFS) as primary and secondary objectives for blinatumomab plus chemotherapy versus chemotherapy alone, but does not provide benchmark results. The ASH 2026 guideline document discusses relapsed/refractory ALL in adolescents and young adults and focuses on treatment recommendations such as "the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction," but does not provide numeric TOT, TTNT, or PFS benchmarks. The supplied document is an ASH guideline for relapsed/refractory acute lymphoblastic leukemia (ALL) in adolescents and young adults and discusses treatment recommendations by regimen and disease setting, but it does not provide published benchmarks for time on treatment, time to next treatment, progression-free survival, or related outcomes by line of therapy. The document identifies treatment modalities and regimens including “blinatumomab,” “inotuzumab,” “CAR T-cell therapy,” and “chemotherapy” in relapsed/refractory B-ALL and references remission status such as “second (or greater) remission (CR2).” The document is a guideline evidence review source rather than an outcomes benchmark dataset. The provided document discusses frontline management recommendations for acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), including regimen selection and supportive care considerations, but it does not provide published benchmarks for time on treatment, time to next treatment, progression-free survival, or related outcomes by line of therapy and regimen. The document does identify frontline therapy approaches and key regimens, particularly pediatric-inspired asparaginase-containing regimens versus adult-inspired protocols. No quantitative benchmark data sources for treatment duration or survival endpoints are reported in the supplied material. The supplied documents do not provide published benchmarks for “time on treatment,” “time to next treatment,” or “progression-free survival” in acute lymphoblastic leukemia stratified by line of therapy and key regimen. The documents instead discuss overall treatment duration and frontline regimen recommendations. One review states that “Contemporary ALL therapy usually consists of cycles of multiagent chemotherapy administered over 2 to 3 years” and that “ALL therapy typically begins with 5 to 9 months of more-intensive chemotherapy followed by a prolonged low-intensity maintenance phase.” The ASH 2026 guideline document provides frontline treatment recommendations for adolescents and young adults, including that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” but it does not report benchmark outcomes such as progression-free survival, time on treatment, or time to next treatment by line of therapy.

National Cancer InstituteNational Cancer Institute (NCI)American Society of HematologyBlood advancesOpen web

What proportion of ALL patients advance from 1L to 2L, 3L, and beyond, and what drives attrition between lines?

Not answered from the sources consulted.